A5043025393- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Chronic Myeloid Leukemia Treatments
- Blood disorders and treatments
- Multiple Myeloma Research and Treatments
- Single-cell and spatial transcriptomics
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- T-cell and B-cell Immunology
- Bone and Joint Diseases
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- Childhood Cancer Survivors' Quality of Life
- Cytomegalovirus and herpesvirus research
Lund University
2016-2025
Massachusetts General Hospital
2023
Skåne University Hospital
2021-2022
University Health Network
2011-2020
Toronto General Hospital
2011-2019
Karolinska Institutet
2007-2018
Karolinska University Hospital
2004-2016
University of Toronto
2011-2016
Sophiahemmet Hospital
2008-2014
Ryhov Hospital Jönköping
2014
To determine the frequency of TP53 mutations and level p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) to assess their impact on disease progression.Pre- postprogression bone marrow (BM) samples from 55 consecutive patients International Prognostic Scoring System low risk (n = 32) or intermediate-1 23) were studied next-generation sequencing TP53. IHC for was performed 148 sequential BM samples.TP53 a median clone size 11% (range,...
To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS).We compared long-term outcome patients with MDS treated EPO G-CSF (n = 121) untreated 237) using multivariate Cox regression delayed entry, for first time adjusting all major prognostic variables (WHO classification, karyotype, cytopenias, level transfusion-need, age, sex).The erythroid response rate to was 39%,...
Summary The bone marrow examination is an essential investigation for the diagnosis and management of many disorders blood marrow. aspirate trephine biopsy specimens are complementary when both obtained, they provide a comprehensive evaluation final interpretation requires integration peripheral blood, findings, together with results supplementary tests such as immunophenotyping, cytogenetic analysis molecular genetic studies appropriate, in context clinical other diagnostic findings....
The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more lineages and increased risk evolution to acute myeloid leukemia (AML). Recent advances immunophenotyping progenitor maturing cells dysplastic bone marrow point useful role for multiparameter flow cytometry (FCM) the diagnosis prognostication syndromes. In March 2008, representatives from 18 European institutes participated LeukemiaNet (ELN) workshop...
Background The current World Health Organization classification of myelodysplastic syndromes is based morphological evaluation bone marrow dysplasia. In clinical practice, the reproducibility recognition dysplasia usually poor especially in cases that lack specific markers such as ring sideroblasts and clonal cytogenetic abnormalities.Design Methods We aimed to develop validate a flow cytometric score for diagnosis syndrome. Four reproducible parameters were analyzed: CD34+...
Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermediate-1-risk (lower-risk) are considered to have an indolent course; however, recent data identified a subgroup of these patients with more aggressive disease and poorer outcomes. Using deep sequencing technology, we previously demonstrated that 18% lower-risk del(5q) carry TP53 mutated subclones rendering them at higher risk progression. In this study, bone marrow biopsies from 85...
Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most protocols focus on the analysis of progenitor cells and evaluation maturing myelomonocytic lineage. However, one most frequently observed features is anemia, which may be associated with dyserythropoiesis. Therefore, changes in nucleated erythroid complement current tools. The multicenter study within IMDSFlow Working Group, reported herein, focused defining parameters that...
Gene expression analysis demonstrated high of the neuronal transcription factor SOX11 in mantle cell lymphoma (MCL). In contrast to follicular lymphoma, small lymphocytic and reactive lymphoid tissue, most MCLs tested (48/53 patients) expressed sox11 protein nucleus. Therefore nuclear represents a new tumour marker for subset MCL. However, 5/53 MCL cases only cytoplasm; these patients had shorter survival compared with expression. These results suggest as diagnostic that could be related...
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase primary myelofibrosis. This discrimination is clinically relevant because associated with a favorable prognosis whereas patients myelofibrosis have higher risk progression to or blast crisis.Design Methods To assess reproducibility classification, six hematopathologists from five European countries re-classified 102 non-fibrotic...
Clonal heterogeneity has not been described in patients with myelodysplastic syndrome isolated del(5q), for which lenalidomide emerged as a highly potent treatment. However, transformation to acute myeloid leukemia is occasionally observed, particularly without cytogenetic response lenalidomide. We performed molecular studies patient classical 5q- complete erythroid and partial lenalidomide, who evolved high-risk complex karyotype. Immunohistochemistry of pre-treatment marrow biopsies...
We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients compared the results with normal B-cell precursors. Early precursors were negative while intermediate mature B cells showed weak expression. Leukemic blasts 31% of precursor-B samples exhibited strong CD123, 61% had moderate 8% negative; 81.5% hyperdiploid karyotype (>/= 52 chromosomes) overexpression. In contrast, cases ETV6/RUNX1 rearrangement Our study suggests that overexpression is an aberrant phenotype present a...
The receptor tyrosine kinase ROR1 has been shown to be overexpressed in chronic lymphocytic leukemia (CLL). aim of this study was further characterize the expression and other member ROR family, ROR2, lymphoid myeloid malignancies. Normal white blood cells reactive lymph nodes were negative for ROR2. A significantly high uniform surface found CLL/hairy cell (HCL) compared mantle lymphoma (MCL), marginal zone (MZL), diffuse large B-cell (DLBCL), follicular (FL), myelomas, acute lymphoblastic...
Few studies describe the comprehensive immunophenotypic pattern of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in bone marrow and its treatment. This retrospective analysis evaluates diagnostic flow cytometry (FCM) outcome nine patients diagnosed with BPDCN. A four-tube 10-color FCM panel used for diagnosis acute leukemia (AL), showed cells blast gate (CD45dim/low SSC) were positive CD4(bright), CD33(dim), CD56(heterogenous), CD123(bright), CD36, CD38, HLA-DR, CD71. Seven received...